Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GENZYME BUYS INTO CELTRIX' TGF-BETA-2 NEURODEGENERATIVE TREATMENT WITH $60 MIL.

Executive Summary

GENZYME BUYS INTO CELTRIX' TGF-BETA-2 NEURODEGENERATIVE TREATMENT WITH $60 MIL. investment that includes equity in the Palo Alto, Calif. biopharmaceutical R&D firm, milestone payments and R&D work, Genzyme announced June 27. Recombinant transforming growth factor-beta-2 (TGF-beta-2, or BetaKine), Celtrix' lead product, will be developed for tissue growth promotion in chronic wounds, for multiple sclerosis treatment and other applications such as dermal wound healing.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024703

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel